SCHEMBL20379548

SCHEMBL20379548

C=C(C)C(=O)N(Cc1ccccc1)C(C)C

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.63
▸ MEN1 O00255 2/20 0.63
▸ LMNA P02545 2/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ ATM Q13315 2/20 0.48
▸ PSEN1 P49768 1/20 0.48
▸ PSEN2 P49810 1/20 0.48
▸ APH1B Q8WW43 1/20 0.48
▸ NCSTN Q92542 1/20 0.48
▸ APH1A Q96BI3 1/20 0.48
▸ PSENEN Q9NZ42 1/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ ALDH1A1 P00352 3/20 0.45
▸ POLB P06746 2/20 0.45
▸ MAPT P10636 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7772334 0.82 KMT2A (0.71) KMT2AMEN1LMNASMN1; SMN2ATM
SCHEMBL1701279 0.82 KMT2A (0.76) KMT2AMEN1LMNASMN1; SMN2ATM
SCHEMBL1629312 0.79 LMNA (0.55) KMT2AMEN1LMNAALDH1A1KDM4E
SCHEMBL628573 0.79 RIPK1 (0.53) KMT2AMEN1LMNAALDH1A1
SCHEMBL30785342 0.78 ALDH1A1 (0.48) KMT2AMEN1LMNAALDH1A1HSD17B10
SCHEMBL13167408 0.77 KMT2A (0.69) KMT2AMEN1LMNASMN1; SMN2ATM
SCHEMBL7972682 0.77 KMT2A (0.69) KMT2AMEN1LMNASMN1; SMN2ATM
SCHEMBL14442982 0.77 KMT2A (0.69) KMT2AMEN1LMNASMN1; SMN2ATM
SCHEMBL2836935 0.77 NPC1 (0.59) KMT2AMEN1SMN1; SMN2ALDH1A1HPGD
Carbamic Acid SCHEMBL7116890 0.77 KMT2A (0.69) KMT2AMEN1LMNASMN1; SMN2ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190382519-A1 CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF ISP INVESTMENTS LLC (US) 2019-12-19 — — US disclosed
WO-2018132548-A1 CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF ISP INVESTMENTS LLC (US) 2018-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190382519-A1 CROSS-LINKED BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES, COMPOSITIONS, AND APPLICATIONS THEREOF ADSL, ABHD6, APH1B KMT2A 3944/4885MEN1 2219/4885LMNA 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback